尿吡啶酚、尿脱氧吡啶酚、尿氨基末端肽在转移性骨肿瘤临床随访价值的应用研究  

Application of Urinary Pyridinium Cross-Links of Collagen (uPyd,uDpd) and Urinary Peptide-Bound Collagen Type Ⅰ Cross-Links N-Telopeptide (uNTx) to the Follow-up for Cancer with Bone Metastases

作　　者：周彤[1] 董春雷[1] 胡岳棣[1] 

机构地区：[1]苏州大学附属常州肿瘤医院,江苏常州213001

出　　处：《肿瘤学杂志》2008年第10期834-836,共3页Journal of Chinese Oncology

基　　金：江苏省常州市科技局资助项目(CS2003204)

摘　　要：[目的]探讨尿吡啶酚(uPyd)、尿脱氧吡啶酚(uDpd)、尿氨基末端肽(uNTx)在肿瘤骨转移患者随访中的应用价值。[方法]晚期肿瘤骨转移患者46例,分别按肿瘤内科治疗原则选用化疗、双膦酸盐治疗、姑息治疗。治疗开始前测定基线uPyd、uDpd、uNTx水平,以后于第1、3个月及以后每3个月检测。记录骨相关不良事件(SRE)。[结果]在1年随访期间,骨转移患者uPyd、uDpd、uNTx水平在含双膦酸盐治疗后1个月有明显下降(P<0.01)。SRE发生时uNTx测定水平与SRE发生前最近一次uNTx测定水平比较有统计学差异(P<0.01),Lg(uNTx/Cr)从2.24±0.12升至2.31±0.13。[结论]uPyd、uDpd、uNTx水平能及时反映抗骨转移治疗特别是双膦酸盐治疗的效果;uNTx水平在SRE发生时有升高趋势,能提示骨病变的进展。[Purpose] To explore the application value of urinary Pyridinium Cross-Links of Collagen （uPyd, uDpd） and urinary Peptide-Bound Collagen Type I Cross-Links N-Telopeptide （uNTx） on follow-up for cancer with bone metastases. [Methods] Forty-six advanced cancer with bone involvement underwent chemotherapy, bisphosphonate therapy and palliative therapy according to the principle of medical ontology. The baselines of uPyd, uDpd and uNTx were quantified at the beginning of the study, then in the first, third, sixth, ninth, twelfth month after treatment, and whenever Skeletal Related Event （SRE） was recorded on follow-up. [Results] In patients with bone metastases whose uPyd, uDpd and uNTx levels decreased obviously in the first month of bisphosphonate based therapy （P〈0.01） during one year follow-up, uNTx increased when SRE occurred in comparison with the most recent measurement before SRE （P〈0.01）. Lg（uNTx/Cr） increased from 2.24±0.12 to 2.31±0.13. [Conclusions] The levels of uPyd, uDpd and uNTx could indicate the therapeutic efficacy of anti-bone metastases especially bisphosphonate based therapy in time. uNTx increases when SRE occurs, which indicates progression of bone disease.

关 键 词：吡啶类 氨基末端肽 骨肿瘤 

分 类 号：R632.101[医药卫生—外科学] R336[医药卫生—临床医学]